Kathryn E Falberg has bought stock on 10 days since Nov 2016

Kathryn E. Falberg is a corporate director and former biotechnology and pharmaceutical finance executive who has served on the board of The Trade Desk, Inc. (NASDAQ: TTD) as an independent director.( At The Trade Desk, she sat on key board committees, including the audit and compensation committees, and was part of the company’s non‑employee director compensation program, receiving annual restricted stock awards in lieu of director retainers and meeting fees.( In March 2026 she executed multimillion‑dollar insider stock sales totaling approximately $4.6 million in Class A common stock, followed later that month by the forfeiture of unvested restricted shares in connection with her decision to resign from the board, effective March 23, 2026; the company noted that her resignation did not stem from any disagreement over its operations, policies, or practices.(

Falberg’s background is in senior financial leadership within the life sciences sector. She previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals from 2012 to 2014, after earlier roles as Senior Vice President and CFO beginning in 2009, where her responsibilities extended beyond finance to strategy, corporate development, corporate communications, and information technology.( Earlier, she held multiple leadership positions at Amgen, including Senior Vice President, Finance and Strategy, and CFO, as well as Vice President, Chief Accounting Officer, and Treasurer.( Falberg has also served on the boards of several public biopharmaceutical companies, including Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, Medivation, and The Trade Desk.( She holds an MBA in finance and a BA in economics from the University of California, Los Angeles, and is a certified public accountant (inactive).(

Written by Perplexity from public sources.